Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several opioid products under development, which would use "Aversion Technology". As of 2014, the company was a publicly traded company, listed on NASDAQ under the symbol "ACUR".

In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.

Aversion Technology, provides abuse deterrent benefits to orally administered pharmaceutical drugs. Many of the products approved by the US Food and Drug Administration, such as OXECTA from Pfizer, have incorporated such technology.

Impede Technology is used in easily dissolved tablets and involves the addition of an inactive ingredient polymer matrix, which has been shown to form a thick gel and start a conversion process of crushed pseudoephedrine (PSE). This technology the aims of the Combat Methamphetamine Epidemic Act enacted in the United States in 2006.

The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.

In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed, which is a drug that attempts to prevent illicit methamphetamine synthesis by incorporating the new pseudoephedrine conversion technology from the company. Nexafed has blocker in it that stops the making of methamphetamine.